MedTrace Logo

Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99

NCT00931086 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2012-10-31

No results posted yet for this study

Summary

An expanded access trial of belimumab for named patients who participated in LBRA99.

Conditions

Interventions

DRUG

belimumab

IV 10mg/kg q28days

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Human Genome Sciences Inc., a GSK Company

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931086 on ClinicalTrials.gov